semaglutide 15 mg Premium Peptide | GLP-1 Agonist Tirzepatide

However, in March 2025, Federal Health Minister Mark Butler wrote to the PBAC to seek their expert advice on equitable access to obesity medicines through the PBS, recognising the potential benefits but also the significant cost to the healthcare system of subsidising these medicines, the spokesperson told newsGP

& Reis, F

B420 is the probiotic strain in the formula, and the published 6-month RCT in 225 overweight and obese adults reported a body fat mass difference of -4.0% versus placebo (P=0.002), a 2.4 cm waist circumference reduction more than placebo, and a daily energy intake reduction of approximately 300 kcal compared to placebo (post-hoc factorial analysis).[9] The trial did not select for GLP-1 users, did not measure constipation as an endpoint, and the available evidence is at the ingredient-level human evidence tier

(More information can be found in Foleys article GLP-1 Drugs: FDA Removes Semaglutide from the Drug Shortage List), The FDA has raised health and safety concerns about these compounded medications, citing issues such as dosing errors, poor inspection records from overseas manufacturers, and, in some instances, adverse events, some of which required medical intervention, These compounded medications are often inaccurately labeled as generic versions of semaglutide and tirzepatide injections and may contain additives, such as vitamins, which have not been approved by the FDA or evaluated through clinical trials, and The FDA has not approved any oral GLP-1 medications, nor has it approved the use of GLP-1 medications for cosmetic purposes

Bodies have built-in weight set points, driven by genetics and environment

Its not a trendits a transformation